Cytokinetics
Empowering Muscle Empowering Lives
Empowering Muscle Empowering Lives
Cytokinetics is a late-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative muscle activators and inhibitors as potential treatments for debilitating diseases affecting muscle performance. As a leader in muscle biology, the company is focused on engineering small molecule drug candidates to impact muscle function and contractility. Notably, Cytokinetics has been recognized as a Best Place to Work by San Francisco Business Times in 2021 and 2022, is certified as a Great Place to Work in 2022, and has been listed in Fortune's Best Workplaces in the Bay Area and in BioPharma in 2022.
Founded in 1998 and based in the United States, Cytokinetics recently received a significant $450.00MPost-IPO Debt investment on July 1, 2022 from Royalty Pharma. The company operates within the biopharma, biotechnology, and health care industries, demonstrating its commitment to addressing unmet medical needs. With its strategic focus and recent investment activity, Cytokinetics continues to position itself as a noteworthy player in the biopharmaceutical landscape.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $550.00M | 1 |
|
22 May 2024 |
| Post-IPO Debt | $50.00M | 1 |
|
22 May 2024 |
| Post-IPO Debt | $450.00M | 1 |
|
01 Jul 2022 |
| Post-IPO Equity | $316.25M | - | 21 Jul 2021 | |
| Post-IPO Equity | $201.30M | - | 16 Jul 2020 |
No recent news or press coverage available for Cytokinetics.
We care about your data, and we'd love to use cookies make your experience better.
